Síguenos en Twitter     Síguenos en Facebook     Síguenos en YouTube     Siguenos en Linkedin     Correo Grupsagessa     Gmail     Dropbox     Instagram     Google Drive     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon


Mi foto
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com


COVID-19 Inflammatory Response in Children & Adults. June 03, 2020



lunes, 18 de mayo de 2020

PCC for emergent VKA reversal

emDocs - May 17, 2020 - By Moussavi K and Quyen N 
Reviewed by: Lentz S; Koyfman A and Long B
"Take Home Points
  • Patients with urgent or emergent need for VKA reversal require IV vitamin K 5-10 mg and PCC.
  • PCC dosing approved by manufacturers for VKA reversal may be complicated, result in excessive administration of clotting factors, and be more expensive than other dosing strategies.
  • Fixed-dose PCC refers to giving a predetermined dose (e.g. 1500 units) instead of a variable dose based on weight and pretreatment INR (e.g. 25-50 units/kg for INR 2 to >6).
  • There is currently limited evidence to support fixed-dose strategies; however, some studies suggest doses 1500-2000 units can provide similar efficacy and safety when compared to weight/INR-based regimens.
  • Fixed doses ≤1000 units may be insufficient for VKA reversal, especially in patients with intracranial hemorrhage.
  • If a fixed dose strategy is adopted, consider adding a re-dose option (e.g. if INR goal not achieved, give remainder of weight/INR-based dose per package insert)."